Form 4: Novavax Director Margaret McGlynn Reports Changes in Beneficial Ownership

Director Margaret McGlynn reports acquisition of Novavax common stock through multiple transactions.

Summary

• Margaret McGlynn, a director of Novavax Inc., filed a Form 4 detailing changes in her beneficial ownership of the company's common stock.
• The report indicates several acquisitions of common stock at varying prices throughout 2024.
• On March 31, 2024, she acquired 2,029 shares at $4.9 per share, increasing her holdings to 5,829 shares.
• On June 30, 2024, she acquired 713 shares at $13.93 per share, increasing her holdings to 13,212 shares.
• On September 30, 2024, she acquired 778 shares at $12.77 per share, increasing her holdings to 13,990 shares.
• On December 31, 2024, she acquired 1,178 shares at $8.61 per share, increasing her holdings to 15,168 shares.
• The filing was signed by Mark J. Casey, Attorney-in-Fact, on February 5, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisitions by a director, which can be interpreted as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• Director's acquisition of shares may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive sign of confidence in the company's future.

Key Dates

Keywords

Novavax, NVAX, Form 4, Beneficial Ownership, Director, Stock Acquisition, Margaret McGlynn